Eltrombopag
- Generic Name
- Eltrombopag
- Brand Names
- Promacta, Revolade
- Drug Type
- Small Molecule
- Chemical Formula
- C25H22N4O4
- CAS Number
- 496775-61-2
- Unique Ingredient Identifier
- S56D65XJ9G
- Background
Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also bee...
- Indication
Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.
- Associated Conditions
- Chronic immune thrombocytopenia, Severe Aplastic Anemia (SAA), Thrombocytopenia
- Associated Therapies
- First-line Therapy
Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 24
- Registration Number
- NCT00909363
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)
- Conditions
- Interventions
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 82
- Registration Number
- NCT00908037
- Locations
- 🇬🇧
GSK Investigational Site, Southampton, United Kingdom
Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation
- First Posted Date
- 2009-05-19
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- Jane Liesveld
- Target Recruit Count
- 19
- Registration Number
- NCT00903929
Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)
- Conditions
- Interventions
- First Posted Date
- 2009-05-14
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 20
- Registration Number
- NCT00902018
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag
- Conditions
- Interventions
- First Posted Date
- 2009-04-28
- Last Posted Date
- 2012-04-20
- Lead Sponsor
- Ingrid Pabinger, MD
- Target Recruit Count
- 30
- Registration Number
- NCT00888901
Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.
- Conditions
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT00833378
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag
- Conditions
- Interventions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT00688272
- Locations
- 🇬🇧
GSK Investigational Site, Dundee, United Kingdom
Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 292
- Registration Number
- NCT00678587
- Locations
- 🇨🇳
GSK Investigational Site, Taoyuan, Taiwan
LENS - Long-term Eltrombopag Observational Study
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 164
- Registration Number
- NCT00643929
- Locations
- 🇬🇧
GSK Investigational Site, Morriston, United Kingdom
Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 759
- Registration Number
- NCT00529568
- Locations
- 🇺🇦
GSK Investigational Site, Vinnitsa, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.